心力衰竭中的empagliflozin与dapagliflozin:一个目标试验仿真试验
Kasper Bonnesen1, Issa J Dahabreh2, Uffe Heide-Jørgensen3
1Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark; Department of Clinical Pharmacology, Copenhagen University Hospital - Bispebjerg and Frederiksberg, Copenhagen, Denmark.
Journal of cardiac failure
|December 31, 2025
概括
与达帕格利弗洛辛相比,恩帕格利弗洛辛可能会减少心力衰竭再入院,但这两种药物在心力衰竭患者的全因死亡风险相似.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 临床研究 临床研究
背景情况:
- 缺乏对心力衰竭的empagliflozin和dapagliflozin之间的直接比较试验.
- -葡萄糖共运输体-2 (SGLT2) 抑制剂越来越多地用于心力衰竭管理.
研究的目的:
- 为了比较在心力衰竭患者中开始使用empagliflozin和dapagliflozin的实际有效性.
- 评估与这些SGLT2抑制剂相关的心力衰竭再住院和全因死亡风险.
主要方法:
- 一个全国性的,前性的,新用户,活跃的比较者队列研究,模拟实用性试验.
- 对心力衰竭再住院和全因死亡的风险进行比较,在开始使用empagliflozin的成年人中与dapagliflozin相比.
- 利用治疗和审查权重的逆概率来平衡共变量并解释不遵守.
主要成果:
- 与达帕格利弗洛辛相比,开始使用empagliflozin与心力衰竭再住院的1年风险较低 (RR,0.81).
- 心力衰竭再住院的五年风险显示,对empagliflozin和dapagliflozin的类似趋势 (RR,0.92).
- 在两种SGLT2抑制剂之间在1年或5年内没有观察到任何原因死亡风险的实质性差异.
结论:
- 与达帕格利弗洛辛相比,恩帕格利弗洛辛在减少心力衰竭再入院方面可能具有潜在的益处.
- 在empagliflozin和dapagliflozin发起者之间没有发现任何原因死亡率的显著差异.
- 这些发现有助于了解SGLT2抑制剂在心力衰竭管理中的比较有效性.
相关概念视频
01:30Heart Failure V: Medical Management
196
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
196
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
874
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
874
01:22Heart Failure Drugs: Diuretics
763
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
763
01:29Heart Failure II: Pathophysiology
663
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
663
01:27Heart Failure I: Introduction
657
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
657
01:23Dipeptidyl Peptidase 4 Inhibitors
547
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
547